CRVS - Corvus Pharmaceuticals, Inc.
| Previous Close | 4.4000 |
| Open | 4.3700 |
| Bid | 0.0000 x 1000 |
| Ask | 0.0000 x 2200 |
| Day's Range | 4.1050 - 4.4550 |
| 52 Week Range | 2.5300 - 8.1000 |
| Volume | 240,534 |
| Avg. Volume | 216,937 |
| Market Cap | 133.639M |
| Beta (5Y Monthly) | 1.32 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.5730 |
| Earnings Date | Oct 28, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.75 |
- GlobeNewswire
Corvus Pharmaceuticals Presents Updated Clinical Data from its Phase 1b/2 Clinical Trial of Ciforadenant at the 2020 American Society of Clinical Oncology’s Genitourinary Cancers Symposium
Corvus Pharmaceuticals, Inc. (CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichment selection, announced updated results from its Phase 1b/2 clinical trial of ciforadenant, an adenosine A2A receptor antagonist, in patients with metastatic castration resistant prostate cancer (mCRPC). The data were presented today in a poster presentation at the American Society of Clinical Oncology 2020 Genitourinary Cancers Symposium (ASCO-GU) in San Francisco by Lawrence Fong, M.D., study investigator and leader of the Cancer Immunotherapy Program at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center.
- GlobeNewswire
Corvus Pharmaceuticals Presents Updated Clinical Data from its Phase 1/1b Clinical Trial of CPI-818 at the 12th Annual T-Cell Lymphoma Forum
Corvus Pharmaceuticals, Inc. (CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichment selection, announced updated results from its Phase 1/1b clinical trial of CPI-818, the Company’s ITK-inhibitor, which were presented today in an oral presentation at the 12th Annual T-Cell Lymphoma Forum in La Jolla, California, taking place January 30 to February 1, 2020. “Our Phase 1/1b clinical trial of CPI-818, our selective covalent ITK inhibitor designed to address T-cell lymphomas, is enrolling well and continues to provide promising clinical data for patients with advanced, refractory forms of this cancer,” said Mehrdad Mobasher, M.D., chief medical officer of Corvus.
- Insider Monkey
Hedge Funds Aren’t Crazy About Corvus Pharmaceuticals, Inc. (CRVS) Anymore
With the first-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the second quarter. One of these stocks was Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS). Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) shareholders have […]
- Simply Wall St.
Read This Before Selling Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Shares
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...
- GlobeNewswire
Corvus Pharmaceuticals Presents Preclinical and Initial Clinical Data from the Phase 1/1b Trial of CPI-818 at the American Society of Hematology (ASH) Annual Meeting
Corvus Pharmaceuticals, Inc. (CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichment selection, announced initial results from its Phase 1/1b trial of CPI-818, the Company’s ITK-inhibitor. The results were presented in a poster at the American Society of Hematology (ASH) 61st Annual Meeting 2019 in Orlando, Florida, taking place December 7-10, 2019. “We are excited to report the first clinical experience with CPI-818, our selective covalent ITK inhibitor designed to address T-cell lymphomas, a category of hematologic cancers with great need for novel therapeutic options,” said Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus.
- GlobeNewswire
Corvus Pharmaceuticals Presents Updated Data from CPI-006 Phase 1/1b Clinical Trial at 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Corvus Pharmaceuticals, Inc. (CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichment selection, today announced updated results from its Phase 1/1b trial of CPI-006, the Company’s anti-CD73 antibody. The clinical data continue to support a novel mechanism of action involving the activation of immune cells potentially directed against tumors, along with the inhibition of adenosine production.
- GlobeNewswire
Corvus Pharmaceuticals to Present Preclinical and Early Clinical Data from the Phase 1/1b Trial with CPI-818 at the American Society of Hematology (ASH) Annual Meeting
BURLINGAME, Calif., Nov. 07, 2019 -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of.
- GlobeNewswire
Corvus Pharmaceuticals to Present at the 28th Annual Credit Suisse Healthcare Conference
BURLINGAME, Calif., Nov. 05, 2019 -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of.
- GlobeNewswire
Corvus Pharmaceuticals to Webcast Investor & Analyst Event on November 8, 2019
Corvus Pharmaceuticals, Inc. (CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichment selection, today announced that it is hosting an investor and analyst event on Friday, November 8, 2019 from 6:00 – 7:30 pm ET, during the Society for Immunotherapy of Cancer (SITC) Annual Meeting in National Harbor, Maryland. The event will be hosted by Corvus president and CEO, Dr. Richard Miller, and will include featured guest Jason J. Luke, M.D., principal investigator of the CPI-006 Phase 1/1b clinical trial and other investigators participating in clinical trials of ciforadenant and the adenosine gene signature in renal cell cancer.
- Thomson Reuters StreetEvents
Edited Transcript of CRVS earnings conference call or presentation 29-Oct-19 8:30pm GMT
Q3 2019 Corvus Pharmaceuticals Inc Earnings Call
- GlobeNewswire
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2019 Financial Results
Corvus Pharmaceuticals, Inc. (CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today provided a business update and reported financial results for the third quarter ended September 30, 2019. “There continues to be strong enrollment in all three of our ongoing clinical studies and we are scheduled to present data related to each at medical meetings during the fourth quarter,” said Richard A. Miller, M.D., president and chief executive officer of Corvus. “The highlight will be the updated data from the CPI-006 study in an oral presentation at SITC in November, which will add to the biologic and clinical evidence supporting CPI-006’s unique dual-mechanisms of action, both in monotherapy and in combination with ciforadenant.
- Simply Wall St.
Companies Like Corvus Pharmaceuticals (NASDAQ:CRVS) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- GlobeNewswire
Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter 2019 Financial Results on October 29, 2019
BURLINGAME, Calif., Oct. 17, 2019 -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of.
- GlobeNewswire
Corvus Pharmaceuticals to Present Updated Data from CPI-006 Clinical Trial at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
BURLINGAME, Calif., Oct. 03, 2019 -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of.
- Simply Wall St.
How Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Can Impact Your Portfolio Volatility
If you own shares in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) then it's worth thinking about how it contributes to...
- Thomson Reuters StreetEvents
Edited Transcript of CRVS earnings conference call or presentation 1-Aug-19 8:30pm GMT
Q2 2019 Corvus Pharmaceuticals Inc Earnings Call
- GlobeNewswire
Corvus Pharmaceuticals to Present at the 2019 Wedbush Healthcare Conference
BURLINGAME, Calif., Aug. 07, 2019 -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of.
- GlobeNewswire
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2019 Financial Results
“Corvus continues to be a leader in the field of drug development targeting the adenosine pathway, with complementary lead programs – ciforadenant and CPI-006 – that have shown promising activity in a range of solid tumors. Together, I believe these three programs position Corvus as a leader in the development of second-generation immuno-oncology agents,” said Richard A. Miller, M.D., president and chief executive officer of Corvus. “At ASCO this year, initial clinical data on CPI-006 was presented in an oral session and subsequently selected for the Highlight of the Day session.
- GlobeNewswire
Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter 2019 Financial Results on August 1, 2019
BURLINGAME, Calif., July 24, 2019 -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of.
- Simply Wall St.
Need To Know: Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Insiders Have Been Buying Shares
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
- GlobeNewswire
Corvus Pharmaceuticals Presents Initial CPI-006 Phase 1/1b Clinical Data at 2019 ASCO Annual Meeting
Corvus Pharmaceuticals, Inc. (CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced initial results from its Phase 1/1b trial of CPI-006, the Company’s anti-CD73 antibody. The initial clinical data from the dose escalation study showed a trend toward longer disease control with higher doses of CPI-006, and enhanced disease control with CPI-006 in combination with ciforadenant (CPI-444) compared with monotherapy, in patients with advanced, refractory cancer.
- GlobeNewswire
Corvus Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference
BURLINGAME, Calif., May 28, 2019 -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of.
- Thomson Reuters StreetEvents
Edited Transcript of CRVS earnings conference call or presentation 9-May-19 8:30pm GMT
Q1 2019 Corvus Pharmaceuticals Inc Earnings Call
- GlobeNewswire
Corvus Pharmaceuticals to Present Initial Clinical Data from CPI-006 Clinical Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
BURLINGAME, Calif., May 16, 2019 -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of.
- Associated Press
Corvus: 1Q Earnings Snapshot
The Burlingame, California-based company said it had a loss of 40 cents per share. In the final minutes of trading on Thursday, the company's shares hit $4.11. A year ago, they were trading at $9.70. _____ ...
